Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)

Table 2 Adverse events of special interest

Adverse Event	Symptom/finding/disease
Pregnancy
Symptomatic overdose
Cancer
Cervical dysplasia
Other autoimmune disease
Infusion-associated reactions	Anaphylactic reactions
Infections	Opportunistic infections, disseminated infections
Diseases of the blood and lymphatic system	Leukopenia, Lymphocytopenia, Thrombozytopenia, Idiopathic thrombocytopenic purpura (ITP), Agranulocytosis, Anemia
Liver disease	Elevated transaminases
CNS diseases	Progressive multifocal leukoencephalopathy (PML)
Renal diseases	Glomerulonephritis
	Nephropathies (e.g. Goodpasture Syndrome)

ISSN: 1471-2377